Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in pediatric Crohn's disease
NL-OMON53505Phase 3Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in Crohn's disease (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Platform-level exploratory clinical remission at Week 52, Platform-level exploratory endoscopic response at Week 52 and 2 more. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON53505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53505.